Zawadzka-Leska S K, Radziszewski M, Malec K, Stadnik A, Ambroziak U
Medical University of Warsaw, Student Scientific Group ENDOCRINUS, Warsaw, Poland.
Medical University of Warsaw, 2 Department of Clinical Radiology, Warsaw, Poland.
Acta Endocrinol (Buchar). 2016 Oct-Dec;12(4):437-442. doi: 10.4183/aeb.2016.437.
Some adrenal tumors, such as pheochromocytoma, can be life-threatening. Therefore it is crucial to distinguish them from other lesions, especially prior to surgery. Chromogranin A (CgA) seems to potentially be a good marker for tumors of chromaffin origin.
To assess the differentiating value of CgA in the diagnostic work-up of pheochromocytoma.
Retrospective study of operated patients with adrenal incidentaloma with lesions > 10 Hounsfield's units (HU) on CT.
Thirty patients (11 males, 19 females; aged 61.5±21 years) were enrolled in the study. Patients using medications interfering with the assessment of CgA and metanephrines were excluded. Two groups were formed: those with pheochromocytoma (Ph, n=16) and those with non-pheochromocytoma (N-Ph, n=14) lesions. Data included radiological features of masses, serum CgA and 24-hour urine metanephrines (24 - HUM) concentrations.
No difference in 24-HUM level nor tumor size or density was found between groups Ph and N-Ph. Median serum CgA concentration was higher in Ph group compared to the N-Ph: 99.35 (68.12-172.73) . 52.92 (34.37-101.26) ng/mL, respectively (P=0.04). In Ph group, the size of the lesion correlated negatively with density (r= -0.53, P=0.042). No significant correlation in CgA, 24-HUM, density or size of the lesion was found. Performed curve receiver operating characteristic (ROC) showed AUC=0.7232 for CgA. Taking into account CgA serum value of ≤ 50 ng/mL (sensitivity: 93.75%, specificity: 50.00%, P=0.012), we proposed an algorithm for management of lesions > 10 HU on CT.
CgA level ≤ 50 ng/mL might be useful in initial screening evidence for the exclusion of pheochromocytoma. It is crucial to eliminate factors interfering with the measurements.
一些肾上腺肿瘤,如嗜铬细胞瘤,可能会危及生命。因此,将它们与其他病变区分开来至关重要,尤其是在手术前。嗜铬粒蛋白A(CgA)似乎可能是嗜铬起源肿瘤的一个良好标志物。
评估CgA在嗜铬细胞瘤诊断检查中的鉴别价值。
对CT上病变>10亨氏单位(HU)的肾上腺偶发瘤手术患者进行回顾性研究。
30例患者(11例男性,19例女性;年龄61.5±21岁)纳入研究。排除使用干扰CgA和甲氧基肾上腺素评估药物的患者。形成两组:嗜铬细胞瘤组(Ph,n = 16)和非嗜铬细胞瘤组(N-Ph,n = 14)。数据包括肿块的放射学特征、血清CgA和24小时尿甲氧基肾上腺素(24-HUM)浓度。
Ph组和N-Ph组之间在24-HUM水平、肿瘤大小或密度方面未发现差异。Ph组血清CgA浓度中位数高于N-Ph组:分别为99.35(68.12 - 172.73)和52.92(34.37 - 101.26)ng/mL(P = 0.04)。在Ph组中,病变大小与密度呈负相关(r = -0.53,P = 0.042)。未发现CgA、24-HUM、病变密度或大小之间存在显著相关性。进行的曲线下面积(ROC)分析显示CgA的AUC = 0.7232。考虑到CgA血清值≤50 ng/mL(敏感性:93.75%,特异性:50.00%,P = 0.012),我们提出了一种针对CT上>10 HU病变的管理算法。
CgA水平≤50 ng/mL可能有助于初步筛查排除嗜铬细胞瘤的证据。消除干扰测量的因素至关重要。